Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study [Breast Cancer]

Conclusion
Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms.

Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Martin, Ruiz Simon, Ruiz Borrego, Ribelles, Rodriguez-Lescure, Munoz-Mateu, Gonzalez, Margeli Vila, Barnadas, Ramos, Del Barco Berron, Jara, Calvo, Martinez-Janez, Mendiola Fernandez, Rodriguez, Martinez de Duenas, Andres, Plazaola, de la Haba-Rodriguez, Tags: Chemotherapy Breast Cancer Source Type: research